New Stock News | Legend Biotech Corp. Sponsored ADR (LEGN.US) plans to conduct a secondary listing outside of the United States with Hong Kong being one of the considered locations.

According to reports, Legend Biotech Corp. Sponsored ADR (LEGN.US) is considering a second listing outside the United States due to strong interest from investors in pharmaceutical companies. The report quotes sources familiar with the matter as saying that possible listing locations include Hong Kong, Singapore, and London. In particular, a second listing in Hong Kong may help to increase Legend Biotech Corp. Sponsored ADR's valuation. The report points out that the decision to conduct a second listing is still under consideration and Legend Biotech Corp. Sponsored ADR may decide not to proceed. Representatives of Legend Biotech Corp. Sponsored ADR declined to comment. Legend Biotech Corp. Sponsored ADR was founded in 2014 and listed on the NASDAQ in the United States in 2020. Its main business is in the field of cancer treatment with CAR-T cell immunotherapy, and its flagship product, Sidakio Lunzai, has been approved for market by the US FDA.